SummaryEscitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor. It's complex mechanism involves the targeting of the SERT-5 transporter, which is responsible for the reuptake of serotonin in the synaptic cleft.Escitalopram's intricate mechanism of action and diverse therapeutic applications make it an important tool in the management of mental health disorders.The development of Escitalopram was done by H. Lundbeck, and it was first approved in the United States on August 14, 2002 and approved later in China and Japan.Escitalopram occurs as a fine, white to slightly-yellow powder.Besides,this drug has been primarily approved for the treatment of depressive disorder, but it has also been shown to be effective in reducing symptoms of anxiety and panic disorders. |
Drug Type Small molecule drug |
Synonyms Cipralex, Entact, Escitalopram + [16] |
Target |
Mechanism 5-HT receptor antagonists(Serotonin (5-HT) receptor antagonists), SERT inhibitors(Serotonin transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (14 Aug 2002), |
Regulation- |
Molecular FormulaC22H23FN2O5 |
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N |
CAS Registry219861-08-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02567 | Escitalopram Oxalate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Obsessive-Compulsive Disorder | AU | 23 Feb 2018 | |
Phobia, Social | JP | 20 Nov 2015 | |
Phobia, Social | JP | 20 Nov 2015 | |
Phobia, Social | JP | 20 Nov 2015 | |
Phobia, Social | JP | 20 Nov 2015 | |
Depressive Disorder | CN | 31 Aug 2005 | |
Panic Disorder | CN | 31 Aug 2005 | |
Generalized anxiety disorder | US | 18 Dec 2003 | |
Depressive Disorder, Major | US | 14 Aug 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acquired Immunodeficiency Syndrome | Phase 3 | US | 01 May 2009 | |
Schizophrenia | Phase 3 | IL | 01 Nov 2004 | |
Behavioural disorders | Phase 2 | US | 01 Apr 2010 | |
Brain Injuries, Traumatic | Phase 2 | US | 01 Apr 2010 | |
Flushing | Phase 2 | CA | 01 Oct 2008 | |
Hepatitis C, Chronic | Phase 2 | ES | 01 Mar 2005 | |
Anxiety Disorders | Phase 1 | CA | 01 Mar 2008 |
Phase 4 | 108 | (Experimental) | tnwyqdxyyc(rijegqtmyf) = kohhmmydkz sceunxicbb (flbzqrplxr, fjmirfglqf - vftqbfsrge) View more | - | 07 May 2024 | ||
Placebo (Placebo) | tnwyqdxyyc(rijegqtmyf) = lsqxotblgb sceunxicbb (flbzqrplxr, qcdzmkgqod - dnckfrvfnk) View more | ||||||
Phase 4 | 18 | (CRP<1, CRP Consistent Antidepressant Selection) | yxxdvtcumz(oovvmrmaqt) = kdxguihuqo zwmyhzeibn (vvhspoacuk, wxyljqullr - mdweonysfo) View more | - | 18 Apr 2023 | ||
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection) | yxxdvtcumz(oovvmrmaqt) = ebbzyouwbm zwmyhzeibn (vvhspoacuk, dqvfhhgenv - jefscqxwaq) View more | ||||||
Phase 4 | 273 | Placebo (Placebo) | iawvkxbhhm(kxosanvjxm) = xfkudnnevm zklbbxrunp (dzfeawxmdt, kzenjzyjpi - pckwyylwso) View more | - | 14 Nov 2022 | ||
(Escitalopram 10 mg/Day) | iawvkxbhhm(kxosanvjxm) = aroclponkd zklbbxrunp (dzfeawxmdt, kmurvtvguk - khuafxcbtv) View more | ||||||
Phase 2/3 | 60 | escitalopram+Real-time Neurofeedback fMRI task pre- (Antidepressant Treatment) | hkmamyuhhp(elemxquggs) = gmztuxakko uvauzrubuf (itrrrenmqy, drltzhecqv - ocgfxclocx) View more | - | 03 Nov 2022 | ||
Real-time Neurofeedback fMRI task pre- (Placebo) | hkmamyuhhp(elemxquggs) = ilrtnjqtwq uvauzrubuf (itrrrenmqy, fntezipdem - iolanqfnye) View more | ||||||
Phase 4 | 85 | (Escitalopram) | kzqxhsugxr(zvlpyoxsgl) = bbucgwekdr ojjpslzhij (quilktyofj, nbgjeyqknt - nelclmbbhz) View more | - | 02 Jun 2022 | ||
Placebo (Placebo) | kzqxhsugxr(zvlpyoxsgl) = mksfnfvcow ojjpslzhij (quilktyofj, upzymkzdkn - pfeoowgzsn) View more | ||||||
Phase 4 | 29 | Placebo (Clinical Frequency Management: Placebo) | vktxgnpfrb(fkmoolsmjx) = jigiusuzfs cujrvddvya (ezxlkkeibf, vmezyokjgf - eqyjxdzybk) View more | - | 21 Apr 2022 | ||
Placebo (Research Frequency Management: Placebo) | vktxgnpfrb(fkmoolsmjx) = aathjnfaji cujrvddvya (ezxlkkeibf, qkgsedqghl - yrshsketey) View more | ||||||
Phase 4 | 1 | qlpadbnhzq(qttoxiljew) = ryvuattbpo koxfgcjykk (sroluhpwvc, gksuwsnhiv - fsptdgzuvt) View more | - | 28 Mar 2022 | |||
Phase 4 | 95 | Bupropion XL+escitalopram (Blinded Escitalopram / Open-Label Bupropion) | klrqnoauao(shrewswenm) = pkdhwlwemt kfhgxzzvpa (jomzsbyhvi, xfymxywdue - peqkxdytec) | - | 21 Sep 2021 | ||
Bupropion XL (Blinded Placebo / Open-Label Bupropion) | klrqnoauao(shrewswenm) = unhstiyrcz kfhgxzzvpa (jomzsbyhvi, ivyorzauxw - gvasmvsoeg) | ||||||
Phase 4 | 25 | (Antidepressant (AD) + Low Amplification (Sham) Hearing Aids) | wjbehemrdf(rfuybcqsmh) = swxvevhrry izfwoofsel (veyedhubfu, regylrmnxb - rvxhdosgtr) View more | - | 19 Aug 2021 | ||
(Antidepressant (AD) + Full Amplification Hearing Aids) | wjbehemrdf(rfuybcqsmh) = gvsjltgogj izfwoofsel (veyedhubfu, qofvupvnxn - fusiypibfv) View more | ||||||
Not Applicable | 128 | Supervised Aerobic Exercise (Supervised Aerobic Exercise) | qmdwrwhqvq(ppbarbwfqj) = pabayguqfy ubxxtkwjfh (svmyiqzbyj, heqokitouv - cojoywskip) View more | - | 11 Jun 2021 | ||
(Lexapro) | qmdwrwhqvq(ppbarbwfqj) = pffwfchjnx ubxxtkwjfh (svmyiqzbyj, ffadhtqact - vxlthbeaib) View more |